Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) is a late clinical-stage biotechnology company focused on developing bacteriophage-based therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. The company's website is www.armatapharma.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Armata Pharmaceuticals, Inc. does
In the company’s own words
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) is a late clinical-stage biotechnology company focused on developing bacteriophage-based therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. The company's website is www.armatapharma.com.
The company leverages proprietary technology to identify, characterize, and develop naturally occurring and engineered bacteriophages combined with host-engineered current Good Manufacturing Practices manufacturing capabilities. Bacteriophages, or phages, are viruses that naturally infect and kill specific bacterial targets while preserving the human microbiome, offering a differentiated mechanism of action compared to broad-spectrum antibiotics.
Armata's clinical pipeline includes two primary product candidates. AP-PA02 is an inhaled phage therapeutic targeting Pseudomonas aeruginosa infections in chronic pulmonary diseases. The company has completed Phase 1b/2a trials in cystic fibrosis patients and Phase 2 trials in non-cystic fibrosis bronchiectasis patients, demonstrating favorable safety profiles and bacterial load reduction. AP-SA02 is an intravenously administered phage cocktail for treating complicated Staphylococcus aureus bacteremia. The company announced positive Phase 1b/2a data in 2025, showing statistically significant clinical response rates and received FDA Qualified Infectious Disease Product designation in February 2026, making it eligible for Fast Track status and additional market exclusivity incentives.
The company is also exploring AP-PA03, an intravenously administered P. aeruginosa phage cocktail for acute ventilator-associated pneumonia and other severe infections, in preclinical development stages.
Armata has received substantial non-dilutive funding, including a $26.2 million award from the U.S. Department of Defense through the Medical Technology Enterprise Consortium and a $5.0 million Therapeutics Development Award from the Cystic Fibrosis Foundation. The company has secured additional financing through credit agreements with Innoviva Strategic Opportunities LLC and entered into a $100 million capital on demand sales agreement in December 2025. Armata maintains a Los Angeles production facility for manufacturing its phage products under cGMP standards and collaborates with regulatory agencies and research institutions to advance phage-based therapeutics as alternatives to traditional antibiotics.
Company details
- Sector
- Healthcare
- Industry
- Biological Products
- Headquarters
- LOS ANGELES, CA
- Fiscal year end
- December
- CIK
- 921114
- SIC
- 2836
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Armata Pharmaceuticals, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Armata Pharmaceuticals, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Armata Pharmaceuticals, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Armata Pharmaceuticals, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Armata Pharmaceuticals, Inc.'s last four quarterly filings that the numbers alone won't show?”